Precision BioSciences (DTIL) Competitors $5.91 +0.02 (+0.34%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$5.94 +0.02 (+0.42%) As of 02/21/2025 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends DTIL vs. CKPT, SLDB, MGNX, OGI, NKTX, ADCT, ENTA, ACTU, NVCT, and TILShould you be buying Precision BioSciences stock or one of its competitors? The main competitors of Precision BioSciences include Checkpoint Therapeutics (CKPT), Solid Biosciences (SLDB), MacroGenics (MGNX), Organigram (OGI), Nkarta (NKTX), ADC Therapeutics (ADCT), Enanta Pharmaceuticals (ENTA), Actuate Therapeutics (ACTU), Nuvectis Pharma (NVCT), and Instil Bio (TIL). These companies are all part of the "pharmaceutical products" industry. Precision BioSciences vs. Checkpoint Therapeutics Solid Biosciences MacroGenics Organigram Nkarta ADC Therapeutics Enanta Pharmaceuticals Actuate Therapeutics Nuvectis Pharma Instil Bio Precision BioSciences (NASDAQ:DTIL) and Checkpoint Therapeutics (NASDAQ:CKPT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations, media sentiment and community ranking. Does the media refer more to DTIL or CKPT? In the previous week, Precision BioSciences had 6 more articles in the media than Checkpoint Therapeutics. MarketBeat recorded 6 mentions for Precision BioSciences and 0 mentions for Checkpoint Therapeutics. Precision BioSciences' average media sentiment score of 0.29 beat Checkpoint Therapeutics' score of 0.00 indicating that Precision BioSciences is being referred to more favorably in the media. Company Overall Sentiment Precision BioSciences Neutral Checkpoint Therapeutics Neutral Do insiders and institutionals hold more shares of DTIL or CKPT? 38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 22.0% of Checkpoint Therapeutics shares are held by institutional investors. 4.0% of Precision BioSciences shares are held by company insiders. Comparatively, 2.1% of Checkpoint Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is DTIL or CKPT more profitable? Precision BioSciences has a net margin of 11.48% compared to Checkpoint Therapeutics' net margin of 0.00%. Checkpoint Therapeutics' return on equity of 0.00% beat Precision BioSciences' return on equity.Company Net Margins Return on Equity Return on Assets Precision BioSciences11.48% -23.69% -6.98% Checkpoint Therapeutics N/A N/A -659.07% Which has better earnings & valuation, DTIL or CKPT? Checkpoint Therapeutics has lower revenue, but higher earnings than Precision BioSciences. Checkpoint Therapeutics is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrecision BioSciences$48.73M0.94-$61.32M$0.0699.18Checkpoint Therapeutics$100K1,540.59-$51.85M-$1.84-1.71 Do analysts rate DTIL or CKPT? Precision BioSciences presently has a consensus price target of $37.67, suggesting a potential upside of 533.05%. Checkpoint Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 280.35%. Given Precision BioSciences' higher possible upside, equities analysts clearly believe Precision BioSciences is more favorable than Checkpoint Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precision BioSciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Checkpoint Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in DTIL or CKPT? Checkpoint Therapeutics received 87 more outperform votes than Precision BioSciences when rated by MarketBeat users. However, 68.38% of users gave Precision BioSciences an outperform vote while only 67.42% of users gave Checkpoint Therapeutics an outperform vote. CompanyUnderperformOutperformPrecision BioSciencesOutperform Votes9368.38% Underperform Votes4331.62% Checkpoint TherapeuticsOutperform Votes18067.42% Underperform Votes8732.58% Which has more risk and volatility, DTIL or CKPT? Precision BioSciences has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500. Comparatively, Checkpoint Therapeutics has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. SummaryPrecision BioSciences beats Checkpoint Therapeutics on 12 of the 16 factors compared between the two stocks. Get Precision BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DTIL vs. The Competition Export to ExcelMetricPrecision BioSciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.56M$3.13B$5.81B$8.95BDividend YieldN/A1.57%4.78%3.85%P/E Ratio99.0230.2926.3918.84Price / Sales0.94320.98451.5276.98Price / CashN/A183.5344.0437.47Price / Book1.313.577.644.65Net Income-$61.32M-$71.72M$3.18B$245.69M7 Day Performance12.90%-2.19%-1.70%-2.42%1 Month Performance30.48%0.72%0.38%-2.14%1 Year Performance-51.86%-11.26%17.43%13.86% Precision BioSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DTILPrecision BioSciences4.3373 of 5 stars$5.91+0.3%$37.67+537.3%-52.2%$45.33M$48.73M98.52200Analyst ForecastNews CoverageCKPTCheckpoint Therapeutics3.1849 of 5 stars$3.31-4.3%$12.00+262.5%+63.0%$161.63M$100,000.00-1.8010Gap DownSLDBSolid Biosciences4.0765 of 5 stars$4.03+2.3%$15.30+279.7%-42.4%$161.04M$8.09M-1.33100Analyst ForecastAnalyst RevisionNews CoverageGap UpHigh Trading VolumeMGNXMacroGenics3.573 of 5 stars$2.56+4.1%$7.63+197.9%-83.8%$160.67M$58.75M-1.62430News CoverageOGIOrganigram0.7264 of 5 stars$1.27-5.9%N/A-34.8%$160.22M$117.47M-3.34860High Trading VolumeNKTXNkarta2.6107 of 5 stars$2.21+4.2%$15.00+578.7%-78.5%$155.96MN/A-1.18140ADCTADC Therapeutics3.0438 of 5 stars$1.61-0.3%$8.00+398.4%-65.1%$155.19M$69.56M-0.67310Short Interest ↓ENTAEnanta Pharmaceuticals4.0957 of 5 stars$7.14-4.8%$17.25+141.6%-38.1%$152.30M$67.64M-1.30160Analyst UpgradeACTUActuate TherapeuticsN/A$7.76+0.4%N/AN/A$151.55MN/A0.0010NVCTNuvectis Pharma2.3951 of 5 stars$7.80+12.2%$21.00+169.2%+7.2%$150.70MN/A-6.728High Trading VolumeTILInstil Bio2.9421 of 5 stars$23.01-3.5%$114.00+395.4%+88.3%$150.26MN/A-1.99410News CoveragePositive News Related Companies and Tools Related Companies Checkpoint Therapeutics Alternatives Solid Biosciences Alternatives MacroGenics Alternatives Organigram Alternatives Nkarta Alternatives ADC Therapeutics Alternatives Enanta Pharmaceuticals Alternatives Actuate Therapeutics Alternatives Nuvectis Pharma Alternatives Instil Bio Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DTIL) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precision BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
